Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Olaparib in Advanced Endometrial Cancer
NCT03951415Phase 2Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in endometrial cancer (EC) and uterine carcinosarcoma (UCS), sponsored by Leiden University Medical Center. Primary endpoint: Progression Free Survival at 6 months. Status: unknown.
02
Drugs
olaparibdurvalumab
03
Conditions
endometrial cancer (EC)uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT03951415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951415.